Nicholas Marston, Brigham and Women’s Hospital, Boston, USA, reviews clinical trial results for apoC3-targeted agents in patients with hypertriglyceridaemia and considers the implications for patients at risk of acute pancreatitis.
Please login or create a FREE account to view this content
Educational Supporters of the 11th Closed Scientific Expert Meeting of the Editorial Board
Principal supporters:
Guest supporters:
